The patient is ultimately the reason why we work in this industry, but historically the patient experience has tended to be sidelined
In Conversation
A lot of work is going on to increase funding for paediatric cancer and many centres – mine included – are not necessarily waiting around for…
If companies bring in the patient perspective from the beginning, the insights they gain could make their clinical trial process go quicker and create a better…
CAR-T, which was touted as a game-changing curative treatment, has been the answer for some patients, but not all
There is great potential for improvement if pharma companies can use agreed-upon standards for collecting data and for data interoperability. Even if the companies do not…
AAM’s policies are consistent with this administration's agenda. We have already had good conversations with the Biden transition team, even before he was sworn in as…
The idea of CIRM was – and continues to be – the building of a regenerative medicine ecosystem in California for vital research opportunities to address…
One of the most common questions we received from clients is, who responded the best during the first wave of the pandemic? The answer is simple:…
While it is true you can make great contributions in academia, I think you can make an even bigger contribution in industry because you are closer…
US physicians have learned that, out of necessity, they have to triage patients through digital tools like teleconferencing and Zoom, which has enabled them to become…
In general, through the global COVID response, we’ve seen the walls between companies and across sectors come down as the industry thinks about tackling this public…
Ultimately, we envision our competition as the disease rather than other companies
